Sinovac Biotech, Ltd
SVA
SVA was delisted on the 22nd of February, 2019.
40 hedge funds and large institutions have $75.9M invested in Sinovac Biotech, Ltd in 2013 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 8 increasing their positions, 13 reducing their positions, and 6 closing their positions.
83% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 6
14% more funds holding
Funds holding: 35 → 40 (+5)
8% more capital invested
Capital invested by funds: $70.4M → $75.9M (+$5.48M)
38% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 13
47% less call options, than puts
Call options by funds: $175K | Put options by funds: $330K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$5.95M |
| 2 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
+$2.73M |
| 3 |
Renaissance Technologies
New York
|
+$954K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$365K |
| 5 |
WC
Wexford Capital
West Palm Beach,
Florida
|
+$337K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DSA
Davis Selected Advisers
Tucson,
Arizona
|
-$1.78M |
| 2 |
O
OrbiMed
New York
|
-$1.49M |
| 3 |
BIM
Bogle Investment Management
Newton Lower Falls,
Massachusetts
|
-$1.32M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$1.04M |
| 5 |
Morgan Stanley
New York
|
-$559K |
SVA Hedge Fund Activity: Q4 2013 in Review
40 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in Sinovac Biotech, Ltd (SVA) for Q4 2013, worth a combined $75.9M — up 7.8% from $70.4M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new SVA positions and 6 closed out — a net gain of 5 holders — while 8 added to existing stakes and 13 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $5.95M. The largest seller was Davis Selected Advisers, cutting an estimated $1.78M.
- 40 institutional investors held Sinovac Biotech, Ltd (SVA) as of Q4 2013, up from 35 in Q3 2013.
- Funds reported $75.9M of Sinovac Biotech, Ltd stock for Q4 2013, up 7.8% quarter-over-quarter.
- 11 funds opened new Sinovac Biotech, Ltd positions in Q4 2013 and 6 closed out, a net change of +5 holders.
- The largest Sinovac Biotech, Ltd buyer in Q4 2013 was Wellington Management Group, an estimated $5.95M added.
- The largest Sinovac Biotech, Ltd seller in Q4 2013 was Davis Selected Advisers, an estimated $1.78M sold.
Based on aggregated 13F filings for Q4 2013.